AI-Powered Precision Decision-Making for Pancreatic Diseases

Summary

This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases. Using contrast-enhanced CT scans, the study compares the AI's recommendations against the decisions of experienced clinicians to verify the system's accuracy and safety in a real-world setting. Patients are categorized into three management groups: Intervention (surgery/treatment), Intensive Surveillance (close monitoring), or Routine Surveillance (standard follow-up). The primary goal is to determine if the AI system can reliably classify patients, reduce the risk of missing malignant lesions, and prevent unnecessary surgeries, thereby improving clinical decision-making for pancreatic conditions.

Eligibility

Inclusion Criteria:

* Clinically suspected pancreatic disease.
* Scheduled to undergo contrast-enhanced CT.
* Signed informed consent form indicating agreement to participate.

Exclusion Criteria:

* History of pancreatic surgery.
* Contraindications to contrast-enhanced CT, including known hypersensitivity to iodinated contrast media or severe renal/hepatic dysfunction.
* Suboptimal image quality affecting diagnosis.
* Concurrent participation in another interventional clinical trial.
* Unsuitability for participation as determined by the investigator, including but not limited to: pregnancy or lactation, severe psychiatric disorders or cognitive impairment, significant comorbidities that may interfere with study results or patient safety.

Conditions8

Browse More Trials